OPKO Completes Pivotal Phase 3 Study for Somatrogon (hGH-CTP), an Investigational Long-Acting Growth Hormone Being Studied for the Treatment of Children With Growth Hormone Deficiency

OPKO Health Reports 2019 Second Quarter Business Highlights and Financial Results

Q2 2019 Financial Results Conference Call

Aug 7, 2019 • 4:30 pm EDT